Pular para o conteúdo
Merck
  • Beta- lactam antibiotics stimulate biofilm formation in non-typeable haemophilus influenzae by up-regulating carbohydrate metabolism.

Beta- lactam antibiotics stimulate biofilm formation in non-typeable haemophilus influenzae by up-regulating carbohydrate metabolism.

PloS one (2014-07-10)
Siva Wu, Xiaojin Li, Manjula Gunawardana, Kathleen Maguire, Debbie Guerrero-Given, Christoph Schaudinn, Charles Wang, Marc M Baum, Paul Webster
RESUMO

Non-typeable Haemophilus influenzae (NTHi) is a common acute otitis media pathogen, with an incidence that is increased by previous antibiotic treatment. NTHi is also an emerging causative agent of other chronic infections in humans, some linked to morbidity, and all of which impose substantial treatment costs. In this study we explore the possibility that antibiotic exposure may stimulate biofilm formation by NTHi bacteria. We discovered that sub-inhibitory concentrations of beta-lactam antibiotic (i.e., amounts that partially inhibit bacterial growth) stimulated the biofilm-forming ability of NTHi strains, an effect that was strain and antibiotic dependent. When exposed to sub-inhibitory concentrations of beta-lactam antibiotics NTHi strains produced tightly packed biofilms with decreased numbers of culturable bacteria but increased biomass. The ratio of protein per unit weight of biofilm decreased as a result of antibiotic exposure. Antibiotic-stimulated biofilms had altered ultrastructure, and genes involved in glycogen production and transporter function were up regulated in response to antibiotic exposure. Down-regulated genes were linked to multiple metabolic processes but not those involved in stress response. Antibiotic-stimulated biofilm bacteria were more resistant to a lethal dose (10 µg/mL) of cefuroxime. Our results suggest that beta-lactam antibiotic exposure may act as a signaling molecule that promotes transformation into the biofilm phenotype. Loss of viable bacteria, increase in biofilm biomass and decreased protein production coupled with a concomitant up-regulation of genes involved with glycogen production might result in a biofilm of sessile, metabolically inactive bacteria sustained by stored glycogen. These biofilms may protect surviving bacteria from subsequent antibiotic challenges, and act as a reservoir of viable bacteria once antibiotic exposure has ended.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Dimetilsulfóxido, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
Dimetilsulfóxido, for molecular biology
Sigma-Aldrich
Dimetilsulfóxido, ACS reagent, ≥99.9%
Sigma-Aldrich
Dimetilsulfóxido, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
Dimetilsulfóxido, suitable for HPLC, ≥99.7%
Sigma-Aldrich
Dimetilsulfóxido, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Dimetilsulfóxido, anhydrous, ≥99.9%
Sigma-Aldrich
Dimetilsulfóxido, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
Dimetilsulfóxido, puriss. p.a., ACS reagent, ≥99.9% (GC)
Sigma-Aldrich
Dimetilsulfóxido, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Ampicillin, anhydrous, 96.0-102.0% (anhydrous basis)
Sigma-Aldrich
Hemin, from bovine, ≥90%
Sigma-Aldrich
Hemin, BioXtra, from Porcine, ≥96.0% (HPLC)
Sigma-Aldrich
Amoxicillin, 95.0-102.0% anhydrous basis
Sigma-Aldrich
Dimetilsulfóxido, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
Dimetilsulfóxido, puriss. p.a., dried, ≤0.02% water
Sigma-Aldrich
Dimetilsulfóxido, PCR Reagent